Analyst Research

Report Title Price
Provider: Finlabo SIM Spa
Provider: Reuters Investment Profile
Provider: ValuEngine, Inc.
Provider: GlobalData

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Sorin SpA Receives Approval of Its Investigational Device Exemption (IDE) Application and Clinical Trial

Monday, 29 Apr 2013 08:22am EDT 

Sorin SpA announced that it has received U.S. Food and Drug Administration (FDA) approval of its Investigational Device Exemption (IDE) application and clinical trial protocol to begin evaluating its PERCEVALS sutureless aortic tissue valve. 

Company Quote

-0.0070 -0.37%
22 Aug 2014